Across both trials, tirzepatide did as well as expected in outperforming a placebo
Sometimes a patient may be interested in an emerging peptide therapy
Inclusion criteria require participants to have evidence of biomarker enrichment at screening, moderately to severely active UC with a baseline mMS of 5-9, inadequate response or intolerance to standard biologic therapy or conventional treatments, while excluding those with severe extensive colitis requiring hospitalization, UC limited to rectum only, presence of ostomy or fistula, history of eosinophilic colitis, or extensive colonic resection
L-CN and GBB concentrations were quantified using D9-l-carnitine and D9--butylbetaine as IS, and both were diluted to 200 ppb by adding 50% methanol in water to the master solution, which was stored at 20 C
Regular updates to our product offerings ensure that you have access to the latest innovations in skincare